News

Merus N.V. Announces Closing of Initial Public Offering

May 25, 2016

UTRECHT, the Netherlands, May 24, 2016 (GLOBE NEWSWIRE) -- Merus N.V. ("Merus") (Nasdaq:MRUS) today announced the closing of its initial public offering of 5,500,000 common shares at an initial public offer...

Merus Announces First Patient Dosed in Phase 1/2 Trial Evaluating Bispecific Antibody Candidate MCLA-117 in Patients with AML

May 04, 2016

Posted on 4 May, 2016 UTRECHT, The Netherlands (GLOBE NEWSWIRE) -- Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, announced today that th...

ISA Pharmaceuticals obtains broad patent protection in the US for proprietary AMPLIVANT® platform and compounds

April 21, 2016

- Granted US patent provides market exclusivity until 2032 - Leiden, The Netherlands, April 19, 2016 - ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immu...

Merus to Present Interim Clinical Data from Ongoing Phase 1/2 Clinical Trial of its Lead Bispecific Antibody Candidate, MCLA-128, at the American Association for Cancer Research 2016 Annual Meeting

April 18, 2016

Posted on 18 April, 2016 MCLA-128 Shows Favorable Safety Profile and Early Signs of Anti-Tumor Activity in Patients with Advanced Solid Tumors UTRECHT, The Netherlands, April 15, 2016 (GLOBE NEWSWIRE)...

ISA Pharmaceuticals' Lead Product ISA101 Efficiently Engages the Immune System Against Virus-Induced Pre-malignant and Malignant Lesions

April 15, 2016

• ISA101 clinically effective against HPV-induced vulvar / vaginal lesions and cervical cancer • Optimum immunotherapy window in cancer identified Leiden, The Netherlands, April 14, 2016 - ISA Pharmaceu...

ORCA Therapeutics raises €1.5 million for funding non clinical evaluation and GMP production of their lead product ORCA-010

April 01, 2016

NIJMEGEN, 01 - 04 - 2016 ORCA Therapeutics B.V. raises € 1.5 Million for the non clinical evaluation and GMP production of t...

Scientific Review Endorses ISA Pharmaceuticals’ Strategy to Overcome Immune Evasion in Cancer Immunotherapy

March 11, 2016

- Targeting and Activating Dendritic Cells is the Key to Success Leiden, The Netherlands, March 11, 2016 - ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, has announced the publication o...

Merus Announces Issuance of Three U.S. Patents Strengthening its Biclonics® Technology Platform for the Discovery and Manufacturing of Human Bispecific Antibodies

March 10, 2016

Utrecht, The Netherlands, March 9, 2016 -- Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, announced today that the United States Patent and Tradem...

Merus and Gustave Roussy Form Strategic Collaboration to Develop Innovative Bispecific Antibodies for Therapeutic Immuno-Oncology Applications

January 05, 2016

UTRECHT, The Netherlands and VILLEJUIF, France, Jan. 04, 2016 (GLOBE NEWSWIRE) -- Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, and Institut Gus...

ISA Pharmaceuticals Appoints Gerben Moolhuizen as Chief Business Development Officer

January 05, 2016

• Seasoned executive brings over twenty years of commercial biotech and pharma experience Leiden, The Netherlands, January 5, 2016 - ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company foc...

Merus Appoints Hui Liu as Chief Business Officer

December 18, 2015

Novartis Oncology's Former Global Head of Business Development and Licensing Joins Immuno-oncology Biotech Company UTRECHT, The Netherlands, Dec. 16, 2015 (GLOBE NEWSWIRE) - Merus B.V., a clinical-stage...

Inthera Bioscience raises EUR 3.4 million in seed financing round

December 15, 2015

Zürich, Switzerland, December 14, 2015 - Inthera Bioscience, a Swiss biopharmaceutical company focused on the development of first-in-class targeted small molecule therapies for solid tumors, today announced...

ISA Pharmaceuticals’ ISA101 Studied in Phase II Combination Trial with Checkpoint Inhibitor Nivolumab

December 07, 2015

• Trial in patients with HPV16-positive, incurable solid tumors initiated by MD Anderson Cancer Center in collaboration with ISA and Bristol-Myers Squibb Leiden, The Netherlands, December 7, 2015 - ISA Ph...

InteRNA Technologies secures final extension Series A financing and strengthens its Supervisory Board

November 13, 2015

Nijmegen/Utrecht (the Netherlands) - InteRNA Technologies B.V., a biopharma company engaged in the development of microRNA (miRNA)-based therapeutics for oncology, announces today the closing of an equity...

Aglaia is co-sponsoring Oncology Drug Development in Practice (ODDP) 2015

August 27, 2015

Aglaia is co-sponsoring the Oncology Drug Development in Practice (ODDP) 2015 training course. The ODDP is a 3-day educational program, offered by Congress by design and INC Research, that teaches knowledge...

Merus enters into 72.8 million euro series C financing led by Sofinnova Ventures and Novo A/S

August 27, 2015

UTRECHT, Netherlands, Aug. 26, 2015 - Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that it has entered into an agreement with i...

Merus Prevails in Inequitable Conduct Case Against Regeneron

August 10, 2015

• Court ruling further strengthens Merus' freedom to operate in using transgenic mice for therapeutic human antibodies Utrecht, The Netherlands, August 10, 2015 -- Merus, a leader in developing best-in-clas...

Towards a Best Practice Approach in Cancer Immunotherapy: Cancer Vaccines Gain Momentum

July 28, 2015

• Review in The Journal of Clinical Investigation points the way forward for therapeutic cancer vaccines Leiden, The Netherlands, July 28, 2015 - ISA Pharmaceuticals B.V., a clinical-stage immunotherapy com...

ISA Pharmaceuticals Further Strengthens IP Position on Lead Compound ISA101

June 23, 2015

• Three additional European patents and market exclusivity granted for the use of key active ingredients of ISA101 Leiden, The Netherlands, June 23, 2015 - ISA Pharmaceuticals B.V., a clinical-stage immun...

Merus appoints Mark Iwicki as President of the Supervisory Board

June 01, 2015

Utrecht, The Netherlands, June 1, 2015 -- Merus B.V., a leader in developing best-in-class bispecific antibody therapeutics to treat cancer patients, today announced that Mark Iwicki has been appointed as Pr...